Your browser doesn't support javascript.
loading
Cancer-associated fibroblasts require proline synthesis by PYCR1 for the deposition of pro-tumorigenic extracellular matrix.
Kay, Emily J; Paterson, Karla; Riera-Domingo, Carla; Sumpton, David; Däbritz, J Henry M; Tardito, Saverio; Boldrini, Claudia; Hernandez-Fernaud, Juan R; Athineos, Dimitris; Dhayade, Sandeep; Stepanova, Ekaterina; Gjerga, Enio; Neilson, Lisa J; Lilla, Sergio; Hedley, Ann; Koulouras, Grigorios; McGregor, Grace; Jamieson, Craig; Johnson, Radia Marie; Park, Morag; Kirschner, Kristina; Miller, Crispin; Kamphorst, Jurre J; Loayza-Puch, Fabricio; Saez-Rodriguez, Julio; Mazzone, Massimiliano; Blyth, Karen; Zagnoni, Michele; Zanivan, Sara.
Afiliação
  • Kay EJ; Cancer Research UK Beatson Institute, Glasgow, UK.
  • Paterson K; Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.
  • Riera-Domingo C; Centre for Microsystems and Photonics, EEE Department, University of Strathclyde, Glasgow, UK.
  • Sumpton D; Laboratory of Tumor Inflammation and Angiogenesis, Center for Cancer Biology (CCB), VIB, Leuven, Belgium.
  • Däbritz JHM; Laboratory of Tumor Inflammation and Angiogenesis, Department of Oncology, KU Leuven, Leuven, Belgium.
  • Tardito S; Cancer Research UK Beatson Institute, Glasgow, UK.
  • Boldrini C; Cancer Research UK Beatson Institute, Glasgow, UK.
  • Hernandez-Fernaud JR; Cancer Research UK Beatson Institute, Glasgow, UK.
  • Athineos D; Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.
  • Dhayade S; Cancer Research UK Beatson Institute, Glasgow, UK.
  • Stepanova E; Cancer Research UK Beatson Institute, Glasgow, UK.
  • Gjerga E; Cancer Research UK Beatson Institute, Glasgow, UK.
  • Neilson LJ; Cancer Research UK Beatson Institute, Glasgow, UK.
  • Lilla S; Translational Control and Metabolism, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Hedley A; Heidelberg University, Faculty of Medicine, Institute for Computational Biomedicine, Bioquant, Heidelberg, Germany.
  • Koulouras G; RWTH Aachen University, Faculty of Medicine, Joint Research Centre for Computational Biomedicine (JRC-COMBINE), Aachen, Germany.
  • McGregor G; Cancer Research UK Beatson Institute, Glasgow, UK.
  • Jamieson C; Cancer Research UK Beatson Institute, Glasgow, UK.
  • Johnson RM; Cancer Research UK Beatson Institute, Glasgow, UK.
  • Park M; Cancer Research UK Beatson Institute, Glasgow, UK.
  • Kirschner K; Cancer Research UK Beatson Institute, Glasgow, UK.
  • Miller C; Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.
  • Kamphorst JJ; Department of Pure and Applied Chemistry, Thomas Graham Building, University of Strathclyde, Glasgow, UK.
  • Loayza-Puch F; Rosalind and Morris Goodman Cancer Research Centre, McGill University, Montreal, Quebec, Canada.
  • Saez-Rodriguez J; Rosalind and Morris Goodman Cancer Research Centre, McGill University, Montreal, Quebec, Canada.
  • Mazzone M; Department of Biochemistry, McGill University, Montreal, Quebec, Canada.
  • Blyth K; Department of Medicine, McGill University, Montreal, Quebec, Canada.
  • Zagnoni M; Department of Oncology, McGill University, Montreal, Quebec, Canada.
  • Zanivan S; Cancer Research UK Beatson Institute, Glasgow, UK.
Nat Metab ; 4(6): 693-710, 2022 06.
Article em En | MEDLINE | ID: mdl-35760868
Elevated production of collagen-rich extracellular matrix is a hallmark of cancer-associated fibroblasts (CAFs) and a central driver of cancer aggressiveness. Here we find that proline, a highly abundant amino acid in collagen proteins, is newly synthesized from glutamine in CAFs to make tumour collagen in breast cancer xenografts. PYCR1 is a key enzyme for proline synthesis and highly expressed in the stroma of breast cancer patients and in CAFs. Reducing PYCR1 levels in CAFs is sufficient to reduce tumour collagen production, tumour growth and metastatic spread in vivo and cancer cell proliferation in vitro. Both collagen and glutamine-derived proline synthesis in CAFs are epigenetically upregulated by increased pyruvate dehydrogenase-derived acetyl-CoA levels. PYCR1 is a cancer cell vulnerability and potential target for therapy; therefore, our work provides evidence that targeting PYCR1 may have the additional benefit of halting the production of a pro-tumorigenic extracellular matrix. Our work unveils new roles for CAF metabolism to support pro-tumorigenic collagen production.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pirrolina Carboxilato Redutases / Neoplasias da Mama / Fibroblastos Associados a Câncer Tipo de estudo: Risk_factors_studies Limite: Female / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pirrolina Carboxilato Redutases / Neoplasias da Mama / Fibroblastos Associados a Câncer Tipo de estudo: Risk_factors_studies Limite: Female / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article